EUROAPI reported first-half 2026 net sales of €356.5 million, down 13.5% year-on-year as reported and 11.8% on a comparable basis, while Core EBITDA fell to €20.7 million from €39.5 million a year earlier. The company posted a net loss of €141.5 million, compared with a loss of €28.5 million in H1 2025, driven by €63.8 million in non-recurring costs tied to its FOCUS-27 transformation plan and a €63.0 million impairment charge. EUROAPI also announced the signing of a share purchase agreement to sell its Brindisi site to Huvepharma for an enterprise value of €5 million, with EUROAPI providing €60 million in transition support over two years. Despite a challenging environment, the company maintained its full-year net sales outlook but adjusted its Core EBITDA margin guidance to around 6%, citing a roughly €9 million adverse impact from the appreciation of the Hungarian Forint.
Euroapi SASH1 net sales down 13.5%, core EBITDA halved, net loss widened to €141.5M from €28.5M, with impairment and transformation costs.
Huvepharma acquires Brindisi site for €5M enterprise value with €60M transition support, gaining a manufacturing asset at low cost.